Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fibrocor Therapeutics Appoints First CEO | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Fibrocor Therapeutics Appoints First CEO

The company is also currently in talks with large pharma partners regarding its pipeline programs

By: Betsy Louda

, Contract Pharma

Fibrocor Therapeutics has appointed Mark Steedman as its first president and chief executive officer. He will also serve as a member of the company’s board of directors.
 

Fibrocor is focused on developing disease modifying therapeutics in fibrosis. Using a first-in class tissue discovery platform, Fibrocor has partnered with Evotec and MI to develop treatments to novel molecular targets and pathways in fibrosis.


Mr. Steedman is the co-founder of Interface Biologics where he most recently served as vice president of Business Development. His responsibilities there included all start-up operations including financing, which led to a Series A round totaling $13 million.

 

“We are extremely pleased to be able to recruit an executive with such extensive knowledge and background in life sciences venture-building” said Rafi Hofstein, president and chief executive officer of MI.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters